Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non Operating Income (2020 - 2025)

Foghorn Therapeutics has reported Other Non Operating Income over the past 6 years, most recently at $502000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at $502000.0 for Q4 2025, down 64.3% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (down 19.26% YoY), and the annual figure for FY2025 was $3.4 million, down 19.26%.
  • Other Non Operating Income for Q4 2025 was $502000.0 at Foghorn Therapeutics, down from $620000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for FHTX hit a ceiling of $1.4 million in Q4 2024 and a floor of -$1.2 million in Q4 2021.
  • Median Other Non Operating Income over the past 5 years was $679000.0 (2021), compared with a mean of $684500.0.
  • Peak annual rise in Other Non Operating Income hit 4507.14% in 2021, while the deepest fall reached 82.09% in 2021.
  • Foghorn Therapeutics' Other Non Operating Income stood at -$1.2 million in 2021, then surged by 152.0% to $624000.0 in 2022, then rose by 8.65% to $678000.0 in 2023, then soared by 107.37% to $1.4 million in 2024, then crashed by 64.3% to $502000.0 in 2025.
  • The last three reported values for Other Non Operating Income were $502000.0 (Q4 2025), $620000.0 (Q3 2025), and $852000.0 (Q2 2025) per Business Quant data.